Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diprobase Cream is a paraffin-based topical emollient used for the symptomatic treatment and relief of dry skin conditions, including eczema, atopic dermatitis, and psoriasis. Manufactured by Bayer, the formulation contains white soft paraffin and liquid paraffin, which act by forming an occlusive oily layer on the skin surface. This physical barrier prevents water loss from the stratum corneum and helps restore the skin's natural barrier function. The cream also contains chlorocresol, which provides antibacterial and antiseptic properties. It was notably evaluated in the Barrier Enhancement for Eczema Prevention (BEEP) trial to determine if early-life application could prevent the development of atopic dermatitis in high-risk infants, though the study found no significant preventative benefit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diprobase Cream (Bayer).